NS Pharma is pleased to announce participation in the Muscular Dystrophy Association’s Clinical & Scientific Congress 2023 being held in Dallas, Texas.
The company will be presenting previously reported long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO®.